Arrowhead Pharmaceuticals, Inc. (ARWR) |
|
24.25 -0.35 (-1.42%)
|
03-22 11:53 |
|
Open: |
24.54 |
Pre. Close: |
24.6 |
|
High:
|
24.885 |
Low:
|
24.02 |
|
Volume:
|
354,969 |
Market Cap:
|
2,627(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:14:16 AM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 34.9 One year: 39.8 |
| Support: |
Support1: 23.09 Support2: 19.21 |
| Resistance: |
Resistance1: 29.88 Resistance2: 34.08 |
| Pivot: |
27.37 |
| Moving Average: |
MA(5): 24.49 MA(20): 28.67
MA(100): 32.76 MA(250): 36.1 |
| MACD: |
MACD(12,26): -2.5 Signal(9): -2.1 |
| Stochastic oscillator: |
%K(14,3): 14.8 %D(3): 13.9  |
| RSI: |
RSI(14): 24.6 |
| 52-week: |
High: 51.11 Low: 23.09 |
| Average Vol(K): |
3-Month: 1,097 (K) 10-Days: 1,694 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARWR ] has closed above bottom band by 21.7%. Bollinger Bands are 58.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
25.57 - 25.71 |
25.71 - 25.82 |
|
Low:
|
24.13 - 24.33 |
24.33 - 24.49 |
|
Close:
|
24.31 - 24.6 |
24.6 - 24.84 |
|
Company Description |
|
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. |
Headline News |
Wed, 22 Mar 2023
Want Diversified Upside in Biotechnology? Check out LABU - Nasdaq
Mon, 20 Mar 2023
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3 - Business Wire
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Kenneth Fisher - 3 ... - Nasdaq
Sat, 11 Mar 2023
Arrowhead Pharmaceuticals, Inc. is sold by BlackRock Inc. for ... - Best Stocks
Tue, 28 Feb 2023
Arrowhead Announces Interim Results from Ongoing Phase 1/2 ... - Business Wire
Thu, 23 Feb 2023
Arrowhead Pharmaceuticals Requires Caution (NASDAQ:ARWR) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
108 (M) |
| Shares Float |
105 (M) |
|
% Held by Insiders
|
4.9 (%) |
|
% Held by Institutions
|
69.3 (%) |
|
Shares Short
|
4,620 (K) |
|
Shares Short P.Month
|
4,580 (K) |
Stock Financials |
|
EPS
|
-1.35 |
|
EPS Est Next Qtl
|
-0.13 |
|
EPS Est This Year
|
-0.42 |
|
EPS Est Next Year
|
-0.67 |
|
Book Value (p.s.)
|
3.54 |
|
Profit Margin (%)
|
-55.6 |
|
Operating Margin (%)
|
-56.6 |
|
Return on Assets (ttm)
|
-12.9 |
|
Return on Equity (ttm)
|
-40.5 |
|
Qtrly Rev. Growth
|
127.9 |
|
Gross Profit (p.s.)
|
2.24 |
|
Sales Per Share
|
2.56 |
|
EBITDA (p.s.)
|
-1.36 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-150 (M) |
|
Levered Free Cash Flow
|
-138 (M) |
Stock Valuations |
|
PE Ratio
|
-17.98 |
|
PEG Ratio
|
-1.4 |
|
Price to Book value
|
6.78 |
|
Price to Sales
|
9.37 |
|
Price to Cash Flow
|
-17.36 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
